Veru Inc VERU

$2.24 -0.05 (-2.18%)

Valuation

Market cap
38,192,000
Revenue TTM
$0
Net income TTM
$-22,730,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
122,500
Avg volume
202,660
Day's range
$2.22 – $2.32
Shares out
17,050,000
Stochastic %K
35%
Beta
-1.21
Analysts
Strong Sell
Price target
$25.67

Price

Company profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective andro...

Show more

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
305 509 6897
Website
https://verupharma.com
Address
2916 North Miami Avenue, Suite 1000, Miami, United States

Latest news

Stocktwits

mrkymrk Oct 20, 5:53 PM
$VERU First patient in for Plateau trial was March 9th. That means the first patients from the trial should be getting their 32 week progress documented from this week forward.
1 replies
Eesnimi Oct 20, 1:00 PM
$VERU Complete crap under $10. Normality starts from 50+
1 replies
mrkymrk Oct 14, 4:15 PM
$VERU Go VERU Go!!!! Keep up the GREAT WORK Mitch and Team!!!! You should get more shares!! You deserve it.
0 replies
RaceMe2TheMoon Oct 14, 2:22 PM
$AKBA today is the day, after 2 years I’ve finally decided to cut my losses on this sh*tty stock. Goodbye. This can go up eventually but I’m not sticking around for years just for this to x2-x4 from this level. If anyone wants exciting prospective stocks, that are not spiraling to 0, check out $RECAF for volume (oil discovery), $SLS for high reward explosive play when phase 3 GPS cancer study results are out (event driven study, that has gone on 2 years more than anticipated, survival rate is that good) results pending any day. And $VERU a personal fun play (no action recently but the leading candidate addressing bone density with GLP-1s. Seems obvious to me)
6 replies
topstockalerts Oct 14, 12:43 PM
Oppenheimer reiterated its Outperform rating on Veru and maintained its $24 price target, reaffirming confidence in enobosarm, the company’s lead obesity-treatment candidate, ahead of a key clinical data update. The analyst expects an interim analysis of the Phase 2b PLATEAU trial, which evaluates enobosarm in combination with semaglutide, to show significant preservation of lean body mass and greater fat loss compared with semaglutide alone. Positive findings could substantially reduce investment risk ahead of the full primary data readout expected in Q4 2027. The trial is fully enrolled with 239 patients, exceeding its original target of 200 participants. Veru also holds a key U.S. patent covering enobosarm and semaglutide combination regimens, with protection expected to extend at least through October 2044, potentially strengthening the program’s long-term commercial positioning. $VERU
2 replies
Chromium Oct 14, 10:20 AM
$VERU any news causing the big drop Tuesday?
1 replies
mrkymrk Oct 13, 8:22 PM
$VERU what to do with all this shareholder value? I think Steiner and the BOD deserve MORE SHARES!!!!
0 replies
Amb8675309 Oct 12, 6:03 AM
$VERU no one will touch Attia anymore. His reputation was ruined by emails sent and received between him and Jeffrey Epstein. One of the most offensive things he said was that he could vouch that pu&&y was “indeed low carb”. I encourage you to look up the scandal that happened in February. I just don’t think you come back from wishing you could get invites to Jeffrey Epstein parties but she also know your son has one month old is in the ICU and you decide to stay in New York and hang out with Jeffrey Epstein..Attia is not a doctor that I would be trusting any information or comments he makes. He had to step down from a CBS position because people were outraged about the hire- they said it showed the network did not care about men who chase young girls and have parties filled with you women… not a good look
1 replies